Product nameHuman Complement C3a des Arg ELISA Kit
Intra-assay Sample n Mean SD CV% Low conc. 16 1.86ng/ml 8.7% Medium conc. 16 3.4ng/ml 9.8% High conc. 16 12.3ng/ml 11.1% Inter-assay Sample n Mean SD CV% Low 0.753ng/ml 5.7% Medium 1.529ng/ml 16.9% High 3.491ng/ml 28.6%
Range0.313 ng/ml - 20 ng/ml
Sample specific recovery Sample type Average % Range Plasma 94.8 % - %
Assay time3h 00m
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Abcam’s Complement C3a des Arg Human in vitro competitive ELISA (Enzyme-Linked Immunosorbent Assay) kit is for the accurate quantitation of Human Complement C3a des Arg in plasma.
A goat anti-rabbit IgG antibody has been precoated onto 96-well plates. Standards or test samples are added to the wells, along with an alkaline phosphatase (AP) conjugated-Complement C3a des Arg antigen and a polyclonal rabbit antibody specific to Complement C3a des Arg. After incubation the excess reagents are washed away. pNpp substrate is added and after a short incubation the enzyme reaction is stopped and the yellow color generated is read at 405 nm. The intensity of the yellow coloration is inversely proportional to the amount of Complement C3a des Arg captured in the plate.
The Human C3a des Arg molecule is one of three activation fragments formed from the activation of the complement cascade. C3a des Arg is formed from C3a via carboxypeptidase cleavage of the C-terminal arginine group. The structure of Human C3a des Arg was first reported in 1975 by Hugli. Human C3a des Arg contains 77 amino acids with 6 cysteines involved in disulfide bridges between residues 22-49, 23-56 and 36-57. The C terminal end of C3a des Arg in Human, porcine, rat, mouse and guinea pig is identical. C3a des Arg is a highly cationic molecule containing no carbohydrate. X-ray crystal data shows the N and C terminal residues to have highly flexible helical structures. C3a is one of the most potent constrictors of smooth muscle cells, and guinea pig airways are hyperresponsive to C3a when pretreated with histamine. The long term study of liver and other transplant recipients for both C3a des Arg and C4a des Arg may be useful in assessing a number of pathological conditions. The use of potent protease inhibitors, such as Futhan, in conjunction with EDTA, may allow complement activation factors to be quantitated specifically via inhibition of non-specific protease formation of C3a des Arg.
Compound Cross Reactivity
Human Complement C3a des Arg
Human Complement C3
Human Complement C4a des Arg
0.40% Human Complement C4 0.31%
Human Complement C5 des Arg
0.10% Human Complement C5 0.05%
Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Storage instructionsPlease refer to protocols.
Components 1 x 96 tests 20X Wash Buffer Concentrate 1 x 30ml Assay Buffer 10 Concentrate 1 x 15ml Complement Reagent A 1 x 15ml Complement Reagent B 1 x 30ml Goat anti-rabbit IgG Microplate (12 x 8 wells) 1 unit Human Complement C3a des Arg EIA Antibody 1 x 6ml Human Complement C3a des Arg EIA Conjugate 1 x 6ml Human Complement C3a des Arg Standard 2 x 500ng Plate Sealer 2 units pNpp Substrate 1 x 23ml Stop Solution 1 x 5ml
RelevanceC3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
- C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1
- Complement C3
ab133037 has been referenced in 3 publications.
- Zhu X et al. All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-IL-1ß loop. Haematologica N/A:N/A (2019). PubMed: 30679324
- Hickman DA et al. Intravenous synthetic platelet (SynthoPlate) nanoconstructs reduce bleeding and improve 'golden hour' survival in a porcine model of traumatic arterial hemorrhage. Sci Rep 8:3118 (2018). PubMed: 29449604
- Zhang X & Sun L Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis. Mol Clin Oncol 8:315-319 (2018). PubMed: 29435296